Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
12 dec 2014 - 07:30
Statutaire naam
Galapagos NV
Titel
Galapagos selects second component of its investigational cystic fibrosis combination treatment
Bericht
Novel corrector GLPG2222 together with potentiator GLPG1837 offers therapy for most CF patients, potentially superior to current therapies under development
Start of Phase 1 with first novel corrector expected before end 2015
Final component for triple combination therapy expected to be nominated in 2015
Mechelen, Belgium; 12 December 2014 - Galapagos NV (Euronext: GLPG) announced today that it nominated a first pre-clinical candidate corrector GLPG2222 for clinical development in its cystic fibrosis (CF) program. This corrector, in combination with GLPG1837, forms the core of Galapagos' future combination therapy for the most common mutation in cystic fibrosis. The Galapagos combination has shown higher efficacy in pre-clinical studies than other therapies currently under clinical development.
Datum laatste update: 01 september 2024